Subtherapeutic triazole concentrations as result of a drug-drug interaction with lumacaftor/ivacaftor
Open Access
- 27 January 2024
- journal article
- research article
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (3) , 563-565
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosisJournal of Cystic Fibrosis, 2022
- Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: II. Therapies for allergic bronchopulmonary aspergillosisPediatric Pulmonology, 2020
- Lumacaftor/ivacaftor initiation in two liver transplantation patients under tacrolimus and antifungal azolesClinical Case Reports, 2019
- Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and CandidiasisEuropean Journal of Drug Metabolism and Pharmacokinetics, 2018
- Fungal Pathogens in CF Airways: Leave or Treat?Mycopathologia, 2017
- Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patientsInfection, 2017
- Therapeutic challenges posed by critical drug–drug interactions in cystic fibrosisPediatric Pulmonology, 2016
- Voriconazole metabolism is influenced by severe inflammation: a prospective studyJournal of Antimicrobial Chemotherapy, 2016
- Fungal epidemiology and diversity in cystic fibrosis patients over a 5-year period in a national reference centerMedical Mycology, 2016